Market Cap 61.61M
Revenue (ttm) 50,000.00
Net Income (ttm) -45.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -91,860.00%
Debt to Equity Ratio 0.00
Volume 228,300
Avg Vol 490,294
Day's Range N/A - N/A
Shares Out 27.75M
Stochastic %K 3%
Beta 0.93
Analysts Strong Sell
Price Target $7.00

Company Profile

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of br...

Industry: Biotechnology
Sector: Healthcare
Phone: 561 710 0512
Address:
225 NE Mizner Blvd., Suite 640, Boca Raton, United States
NachoBusiness
NachoBusiness Sep. 11 at 6:29 PM
$INMB momentum seems to be slipping away
0 · Reply
NachoBusiness
NachoBusiness Sep. 10 at 2:58 PM
$INMB Sold half at 2.54 yesterday, rebuying in now. Saved a decent loss.
0 · Reply
NachoBusiness
NachoBusiness Sep. 9 at 10:50 AM
$INMB 2.45/2.50 ask
0 · Reply
NachoBusiness
NachoBusiness Sep. 8 at 8:21 PM
$INMB pinned right back to 2.49 Crazy
0 · Reply
RadioIsotope25
RadioIsotope25 Sep. 8 at 6:12 PM
Cordstrom doesn’t do much for patients. Not sure who would even buy this drug $INMB
3 · Reply
zampy
zampy Sep. 8 at 3:49 PM
$INMB Volume precedes price HOY! Short covering??? News???? Submission UK MHRA MAA???
0 · Reply
NachoBusiness
NachoBusiness Sep. 8 at 3:32 PM
$INMB Here comes the dip, 74k shares in 2 candles. Needs to hold $2.50
0 · Reply
dipsandchipssss
dipsandchipssss Sep. 8 at 3:32 PM
$INMB veryyyy interesting
0 · Reply
Muscle24
Muscle24 Sep. 8 at 2:33 PM
$INMB New 52 WH…..hell yeahhhhhhh😋
0 · Reply
dipsandchipssss
dipsandchipssss Sep. 8 at 2:21 PM
$INMB 2.50$?
0 · Reply
Latest News on INMB
INmune Bio Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

INmune Bio Earnings Call Transcript: Q2 2026


INmune Bio Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

INmune Bio Quarterly report: Q2 2026


INmune Bio Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

INmune Bio Earnings release: Q2 2026


INmune Bio receives $4.6M in rebates from Australia, UK

2026-07-31T11:05:59.000Z - 6 weeks ago

INmune Bio receives $4.6M in rebates from Australia, UK


INmune Bio Receives R&D Rebates of Approximately $4.6 Million

Jul 31, 2026, 7:00 AM EDT - 6 weeks ago

INmune Bio Receives R&D Rebates of Approximately $4.6 Million


INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

Jun 25, 2026, 7:00 AM EDT - 2 months ago

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™


INmune Bio Transcript: AGM 2026

Jun 16, 2026, 10:00 AM EDT - 2 months ago

INmune Bio Transcript: AGM 2026


INmune Bio Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 3 months ago

INmune Bio Slides: Corporate presentation


INmune Bio publishes MINDFuL trial results in NPJ Dementia

2026-05-15T13:24:06.000Z - 4 months ago

INmune Bio publishes MINDFuL trial results in NPJ Dementia


INmune Bio receives fast track designation from FDA for XPro

2026-05-14T14:59:02.000Z - 4 months ago

INmune Bio receives fast track designation from FDA for XPro


INmune Bio Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

INmune Bio Earnings Call Transcript: Q1 2026


INmune Bio Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

INmune Bio Earnings release: Q1 2026


INmune Bio Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

INmune Bio Quarterly report: Q1 2026


INmune Bio Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

INmune Bio Proxy statement: Proxy filing


INmune Bio announces new preclinical data for INB03

2026-04-16T14:16:48.000Z - 5 months ago

INmune Bio announces new preclinical data for INB03


INmune Bio Earnings Call Transcript: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 5 months ago

INmune Bio Earnings Call Transcript: Q4 2025


INmune Bio Annual report: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 5 months ago

INmune Bio Annual report: Q4 2025


INmune Bio Earnings release: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 5 months ago

INmune Bio Earnings release: Q4 2025


INmune Bio upgraded to Buy from Neutral at Lucid Capital

2026-03-11T10:11:18.000Z - 6 months ago

INmune Bio upgraded to Buy from Neutral at Lucid Capital


INmune Bio Slides: Corporate presentation

Mar 10, 2026, 7:00 AM EDT - 6 months ago

INmune Bio Slides: Corporate presentation


INmune Bio Transcript: Study update

Feb 26, 2026, 1:00 PM EST - 6 months ago

INmune Bio Transcript: Study update


INmune Bio publishes study on INmune’s CORDStrom platform

2025-12-05T12:10:33.000Z - 9 months ago

INmune Bio publishes study on INmune’s CORDStrom platform


INmune Bio reports Q3 EPS (24c), consensus (32c)

2025-10-30T20:46:45.000Z - 10 months ago

INmune Bio reports Q3 EPS (24c), consensus (32c)


INmune Bio Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 10 months ago

INmune Bio Earnings Call Transcript: Q3 2025


INmune Bio Earnings release: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 10 months ago

INmune Bio Earnings release: Q3 2025


INmune Bio Quarterly report: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 10 months ago

INmune Bio Quarterly report: Q3 2025


INmune Bio Proxy statement: Proxy Filing

Oct 14, 2025, 8:00 AM EDT - 11 months ago

INmune Bio Proxy statement: Proxy Filing


INmune Bio Proxy statement: Proxy Filing

Oct 3, 2025, 8:00 AM EDT - 11 months ago

INmune Bio Proxy statement: Proxy Filing


INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia

2025-09-29T12:20:16.000Z - 11 months ago

INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia


INmune Bio Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q2 2025


INmune Bio Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q2 2025


INmune Bio Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q2 2025


INmune Bio Slides: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Slides: Q2 2025


INmune Bio Transcript: Status Update

Jun 30, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Transcript: Status Update


INmune Bio Press release: Status Update

Jun 30, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Press release: Status Update


INmune Bio Proxy statement: Proxy Filing

May 9, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing


INmune Bio Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q1 2025


INmune Bio Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q1 2025


INmune Bio Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q1 2025


INmune Bio Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing


INmune Bio Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing


INmune Bio Slides: Corporate Presentation

Apr 3, 2025, 7:00 AM EDT - 1 year ago

INmune Bio Slides: Corporate Presentation


INmune Bio Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q4 2024


INmune Bio Earnings release: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q4 2024


INmune Bio Annual report: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Annual report: Q4 2024


INmune Bio Transcript: Study Result

Feb 10, 2025, 8:30 AM EST - 1 year ago

INmune Bio Transcript: Study Result


INmune Bio Earnings Call Transcript: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q3 2024


INmune Bio Earnings release: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q3 2024


INmune Bio Quarterly report: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q3 2024


NachoBusiness
NachoBusiness Sep. 11 at 6:29 PM
$INMB momentum seems to be slipping away
0 · Reply
NachoBusiness
NachoBusiness Sep. 10 at 2:58 PM
$INMB Sold half at 2.54 yesterday, rebuying in now. Saved a decent loss.
0 · Reply
NachoBusiness
NachoBusiness Sep. 9 at 10:50 AM
$INMB 2.45/2.50 ask
0 · Reply
NachoBusiness
NachoBusiness Sep. 8 at 8:21 PM
$INMB pinned right back to 2.49 Crazy
0 · Reply
RadioIsotope25
RadioIsotope25 Sep. 8 at 6:12 PM
Cordstrom doesn’t do much for patients. Not sure who would even buy this drug $INMB
3 · Reply
zampy
zampy Sep. 8 at 3:49 PM
$INMB Volume precedes price HOY! Short covering??? News???? Submission UK MHRA MAA???
0 · Reply
NachoBusiness
NachoBusiness Sep. 8 at 3:32 PM
$INMB Here comes the dip, 74k shares in 2 candles. Needs to hold $2.50
0 · Reply
dipsandchipssss
dipsandchipssss Sep. 8 at 3:32 PM
$INMB veryyyy interesting
0 · Reply
Muscle24
Muscle24 Sep. 8 at 2:33 PM
$INMB New 52 WH…..hell yeahhhhhhh😋
0 · Reply
dipsandchipssss
dipsandchipssss Sep. 8 at 2:21 PM
$INMB 2.50$?
0 · Reply
10baggerPete
10baggerPete Sep. 7 at 7:54 PM
$INMB closing in on 5,000 watchers .... New beginnings
1 · Reply
zampy
zampy Sep. 5 at 1:40 PM
$INMB This will be the 1st year INMB will not be a tax loss candidate!! I believe gap fill at $3.....I think we see $5 in the next 3 months.
0 · Reply
topstockalerts
topstockalerts Sep. 5 at 12:18 AM
$INMB that was a much stronger response than expected.
0 · Reply
Muscle24
Muscle24 Sep. 4 at 7:55 PM
$INMB Very strong price action!!!!!! Super bullish!!!
1 · Reply
NachoBusiness
NachoBusiness Sep. 3 at 2:00 PM
$INMB 2.40 needs to hold , volume is still very low
0 · Reply
zampy
zampy Sep. 3 at 11:48 AM
$INMB Bren adding 2.22 to 2.35....Het ready submission...
0 · Reply
NachoBusiness
NachoBusiness Aug. 31 at 1:35 PM
$INMB $2.16 and 1.97 then 1.79 on board if this continues to sell off. Not good
0 · Reply
Eye_ater
Eye_ater Aug. 28 at 9:01 PM
$SLS Interesting background on today's BMF $SLS short report: BMF and Martin Shkreli aren't exactly strangers. • BMF recently replied directly to @MartinShkreli about $BLZE and retweeted him during the $CAPR blowup: https://mobile.twstalker.com/BmfReports • There's precedent with $INMB. Shkreli publicly attacked INmune Bio, and BMF later published its own bearish INMB report: https://bmfreports.com/articles/inmb • Shkreli has been aggressively bearish on $SLS and was still predicting failure just days before today's BMF report: https://www.kazuha.ai/sources/martin-shkreli/posts/8-25-26-5-since-7-1 Now BMF releases a short report on $SLS containing several overlapping bear arguments. Does this prove Shkreli commissioned or coordinated the report? NO. But BMF has interacted with Shkreli, amplified his content, previously targeted another biotech he attacked, and now targets one of his highest-conviction shorts. Could be completely independent, but interesting.
1 · Reply
NachoBusiness
NachoBusiness Aug. 28 at 4:01 PM
$INMB Nasty rejection from 2.50
0 · Reply
NachoBusiness
NachoBusiness Aug. 28 at 2:16 PM
$INMB Shorts got it back down to 2.34, If this doesn’t hold 2.25, it could see sub $2
0 · Reply
NachoBusiness
NachoBusiness Aug. 27 at 1:49 PM
$INMB this stock loves resistance points
0 · Reply
DonCorleone77
DonCorleone77 Aug. 26 at 11:17 AM
$INMB INmune Bio submits two regulatory packages to EMA for Ebstrocel INmune Bio announced that it has submitted two regulatory packages to the European Medicines Agency, or EMA, for Ebstrocel: an application for orphan drug designation and a scientific advice package to streamline the upcoming marketing authorization application, or MAA, in Europe. Ebstroce is an investigational pooled, allogeneic, umbilical cord-derived mesenchymal stromal cell therapy being developed as a systemic treatment for recessive dystrophic epidermolysis bullosa. The EMA filings are intended to support the company's planned EU MAA in Q1 2027 and form part of a coordinated global registration strategy that includes a planned UK MAA in Q4 2026 and a planned U.S. biologics license application in Q1 2027.
1 · Reply